help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rupprecht, R.
Right arrow Articles by Schulte, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rupprecht, R.
Right arrow Articles by Schulte, H. M.
Right arrowPubmed/NCBI databases
*Substance via MeSH

Journal of Clinical Endocrinology & Metabolism, Vol 69, 600-603, Copyright © 1989 by Endocrine Society

ARTICLES

Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression

R Rupprecht, KP Lesch, U Muller, G Beck, H Beckmann and HM Schulte
Psychiatrische Klinik, University of Wurzburg, West Germany.

Since the discovery of CRH in 1981, several investigators have reported abnormalities of the hypothalamic-pituitary-adrenal (HPA) system in response to direct stimulation of the corticotroph cells in patients with psychiatric disorders. To further explore HPA system integrity in major depressive disorders, 13 drug-free patients and normal subjects matched for age, sex, ovarian status, and body weight received 100 micrograms synthetic human CRH as an iv bolus dose. Compared to that in the normal subjects, in the depressed patients a significant attenuation of the net ACTH release after CRH administration (772 +/- 597 vs. 263 +/- 286 pmol/min.L; P less than 0.02) was observed, while beta-endorphin and cortisol responses did not differ significantly between the groups. The magnitudes of ACTH and cortisol release were negatively correlated in the patient group only (r = -0.67; P less than 0.01). Thus, the blunted ACTH response to CRH in depression might be related to hypercortisolemia, while the implications of the apparent dissociation of ACTH and beta-endorphin after CRH administration still remain unclear. Our data support the hypothesis that the hyperactivity of the HPA system in depression most likely is a consequence of CRH hypersecretion, the origin of which may be explained by abnormal central glucocorticoid receptor or neurotransmitter regulation.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
J. Newell-Price, P. Trainer, M. Besser, and A. Grossman
The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States
Endocr. Rev., October 1, 1998; 19(5): 647 - 672.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. A. Yanovski, G. B. Cutler Jr., G. P. Chrousos, and L. K. Nieman
The Dexamethasone-Suppressed Corticotropin-Releasing Hormone Stimulation Test Differentiates Mild Cushing's Disease from Normal Physiology
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 348 - 352.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society